Prelude Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Prelude Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-32,840	Closed	-$89.7K	–	1271
2025 Q3	$89.7K	Sell	32,840 -8,869	-21%	-$29.5K	0.01%	1065
2025 Q2	$152K	Sell	41,709 -88,579	-68%	-$243K	0.01%	854
2025 Q1	$250K	Buy	130,288 +37,137	+40%	+$75.8K	0.02%	803
2024 Q4	$177K	Buy	+93,151	New	+$162K	0.01%	1019
2020 Q4	–	Sell	-30,888	Closed	-$78K	–	1245
2020 Q3	$78K	Buy	+30,888	New	+$271K	﹤0.01%	989
2019 Q3	–	Sell	-1,408	Closed	-$7K	–	1679
2019 Q2	$7K	Buy	+1,408	New	+$8.01K	﹤0.01%	1455
2019 Q1	–	Sell	-559	Closed	-$3K	–	1733
2018 Q4	$3K	Sell	559 -215	-28%	-$1.68K	﹤0.01%	1666
2018 Q3	$7K	Sell	774 -6,357	-89%	-$56.9K	﹤0.01%	1567
2018 Q2	$71K	Sell	7,131 -5,252	-42%	-$52.6K	﹤0.01%	1026
2018 Q1	$118K	Buy	+12,383	New	+$173K	0.01%	825
2017 Q1	–	Sell	-5,100	Closed	-$53K	–	1478
2016 Q4	$53K	Buy	+5,100	New	+$43.9K	0.01%	1023

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prelude Capital Management's AKBA Position: Q4 2025 in Review

Prelude Capital Management sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 32,840 shares — an estimated $89.7K sold.

Prelude Capital Management first reported a position in AKBA in Q4 2016 and held it in 11 quarters. The position peaked at $250K in Q1 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

Prelude Capital Management reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
Prelude Capital Management sold 32,840 Akebia Therapeutics shares in Q4 2025, an estimated $89.7K.
Prelude Capital Management first reported a position in Akebia Therapeutics in Q4 2016 and held it in 11 quarters.
Prelude Capital Management's Akebia Therapeutics position peaked at $250K in Q1 2025.
165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.